SOZO

by ImpediMed Limited  · Based in United States →The world’s most advanced, non-invasive bioimpedance spectroscopy (BIS) device for lymphedema detection and management.
General Surgery Oncology

Documentation ProvidedRegulatory Status Disclosed

Overview

The SOZO Digital Health Platform by ImpediMed is a cutting-edge, non-invasive bioimpedance spectroscopy (BIS) device designed to provide physicians with objective data for the early detection and ongoing management of lymphedema. Utilizing advanced BIS technology, SOZO offers a rapid, 30-second scan to measure extracellular fluid changes, a key indicator of lymphedema development. This proactive approach empowers clinicians to intervene earlier, potentially preventing the progression of lymphedema to more severe and debilitating stages.

SOZO generates an L-Dex score, a standardized index that quantifies fluid changes, enabling precise monitoring of patients at risk or those already undergoing lymphedema treatment. Beyond lymphedema, the device also performs comprehensive body composition analysis, providing insights into fluid status, body fat, and lean mass. This dual functionality makes SOZO a versatile tool for various clinical settings, from oncology and rehabilitation to general wellness and chronic disease management.

The platform is cloud-based, allowing for seamless data management, trend analysis, and secure access to patient information. Physicians can track changes over time, assess treatment efficacy, and personalize care plans based on objective, longitudinal data. SOZO’s intuitive touchscreen interface and wireless connectivity ensure ease of use within busy clinical workflows, while automated reporting streamlines documentation.

By integrating SOZO into their practice, physicians can enhance patient care through early intervention, improve patient outcomes, and provide a more data-driven approach to managing lymphedema and related conditions. The “my SOZO” patient portal further supports patient engagement by allowing individuals to access and understand their results, fostering a collaborative approach to health management.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Bioimpedance Spectroscopy (BIS) technology
  • L-Dex score for lymphedema assessment
  • Rapid, non-invasive 30-second scan
  • Body composition analysis (fluid, fat, lean mass)
  • Cloud-based data management and trend analysis
  • Wireless connectivity & intuitive touchscreen
  • Automated reporting
  • My SOZO patient portal access
  • FDA-cleared technology
  • Objective, longitudinal data tracking

Use Cases

  • Early detection of lymphedema in at-risk populations (e.g., post-cancer treatment)
  • Monitoring lymphedema progression and treatment effectiveness
  • Pre-surgical baseline assessment for patients undergoing procedures with lymphedema risk
  • Post-surgical surveillance for lymphedema development
  • Comprehensive body composition analysis for general health and wellness
  • Personalized care planning and patient education based on objective data

What Physicians Need to Know

Evidence Base
SOZO's Bioimpedance Spectroscopy (BIS) technology is supported by clinical practice guidelines, including the NCCN Clinical Practice Guidelines in Oncology for Survivorship, which recommend BIS for lymphedema screening. The PREVENT trial, the largest randomized controlled trial for lymphedema assessment, demonstrated a 92% reduction in progression to chronic lymphedema with BIS technology and early intervention. The L-Dex score, central to SOZO, is the first FDA-cleared BIS technology for lymphedema assessment.
Clinical Validation Studies
The PREVENT trial is a key validation study, showing a significant reduction in chronic lymphedema progression when BIS technology and early intervention are used. SOZO is FDA-cleared for lymphedema assessment and its effectiveness is reinforced by other clinical research.
Alert Fatigue Management
SOZO's L-Dex score utilizes built-in thresholds and longitudinal tracking to identify subtle changes that may indicate early-stage lymphedema. The system provides a Lymphedema Prevention Program (LPP) Protocol Compliance Dashboard that highlights patients above the L-Dex trigger for subclinical lymphedema, aiding in proactive management.
Guideline Update Frequency
SOZO's cloud-connected architecture enables remote software and firmware updates. While the device itself receives updates, the frequency of updates for the clinical guidelines referenced within the SOZO system is not explicitly stated, though national guidelines like NCCN are regularly updated.
Clinical Workflow Integration
SOZO is designed for seamless integration into existing clinical workflows, allowing scans to be incorporated into standard vital sign intake. Results are instantly uploaded to a secure cloud platform, making them accessible to the entire care team. SOZO 4.1 software and SOZO Pro enable automatic transfer of measurement data directly into Electronic Health Record (EHR) systems, eliminating manual data entry and improving workflow efficiency.
Decision Audit Trail
The MySOZO web-based application provides administrators with access to security logs and audit reports. Login information, including successful and failed attempts, user accounts, and timestamps, is logged and cannot be modified by end-users or ImpediMed staff, contributing to a system audit trail.
Physician Tip

Leverage SOZO for objective, early detection and proactive management of lymphedema, particularly in at-risk cancer patients, by establishing baseline L-Dex measurements. Utilize its capabilities for fluid and body composition monitoring in other relevant conditions. Integrate SOZO scans into routine patient visits to streamline data collection and enhance care coordination through its EHR integration.

SOZO offers robust integration with Electronic Health Record (EHR) systems, including Epic, Cerner, and others, allowing for automatic, real-time transfer of measurement data. Its cloud-based platform ensures data accessibility for multidisciplinary care teams and facilitates remote software updates.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics
Pricing Unknown unknown
DeploymentCloud
Data Export Yes
LanguagesEnglish
Training Yes
Target SizeSolo to large health systems
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated — K190529
FDA Pathway510(k) AI-estimated
CPT Codes93702
Clinical Evidence

SOZO's L-Dex® accuracy was calculated with an area under the curve (AUC) of 0.95 for unilateral assessment and 0.80 for bilateral assessment. The PREVENT trial, the largest randomized clinical trial to assess lymphedema prevention, has resulted in eight peer-reviewed publications supporting SOZO's efficacy. Fluid measurements using BIS are validated against gold standard isotopic dilution techniques, and tissue measurements against DXA.

AI-estimated
Integrations
Integration MethodSOZO integrates with clinical systems via an EHR interface, allowing automatic transfer of measurement data directly into electronic health record systems. The platform is cloud-connected, enabling real-time data access and sharing across an organization.
EHR Not specified
Specialties General Surgery, Oncology

Social Proof

CustomersOver 1,100 devices in use globally; 500,000+ patient tests performed (as of Nov 2022)

Support & Reliability

Training Provided Yes

What the Web Says

SOZO, a medical device for lymphedema assessment, generally receives positive feedback for its non-invasive approach and early detection capabilities. Physicians appreciate its role in improving patient outcomes by identifying lymphedema at subclinical stages, allowing for timely intervention. However, some reviews mention the cost of the device and the need for proper training to ensure accurate readings as potential drawbacks.

Overall: Positive

Strengths

  • Non-invasive and quick measurement
  • Early detection of lymphedema (subclinical)
  • Objective data for patient monitoring
  • Improved patient outcomes through early intervention
  • Easy to use for trained professionals
  • Reduces need for more invasive tests

Limitations

  • Cost of the device can be a barrier for some clinics
  • Requires proper training for accurate results
  • May not be covered by all insurance plans
  • Some users report a learning curve
  • Limited data on long-term comparative effectiveness against other methods
  • Calibration and maintenance requirements

Based on reviews from: Reddit, G2, Capterra, Healthcare IT News, Physician forums, Medical device review sites

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate SOZO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
ImpediMed Broadens Breast Cancer Survivorship Monitoring with the SOZOu00ae Digital Health Platform at ASBrS 2026
ImpediMed announced an expanded clinical vision for breast cancer survivorship care at ASBrS 2026, showcasing its SOZO Digital Health Platform with L-Dexu00ae and BodyCompu2122 Analysis for integrated fluid and body composition monitoring.
2026-05
SOZO Brain Center
Inside SOZO Conference 2025: Transforming Brain Health Globally
The 2nd Annual SOZO Neuromodulation Conference in December 2025 brought together experts to explore neuromodulation therapies, with plans for global partnerships and initiatives in 2026 to expand SOZO Brain Center's reach.
2025-12
CRC Press
Activity, Behavior, and Healthcare Computing | Sozo Inoue, Guillaume L
This book, published in February 2025, covers activity, behavior, and healthcare computing, with Sozo Inoue as one of the editors.
2025-02
Michigan Cannabis Regulatory Agency
STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS CANNABIS REGULATORY AGENCY In the Matter of Sozo Health, Inc.
A formal complaint was filed against Sozo Health, Inc. in January 2024 for violating Michigan administrative code related to advertising marijuana products.
2024-01
PR Newswire
FDA Grants Breakthrough Device Designation for ImpediMed's SOZOu00ae Digital Health Platform for Renal Failure
ImpediMed's SOZO Digital Health Platform received Breakthrough Device Designation from the FDA in August 2021 for its potential to more precisely measure fluid volume in renal failure patients during dialysis.
2021-08
ImpediMed (ASX Announcement)
AstraZeneca Selects SOZO for Heart Failure & Renal Trials Key Highlights
In September 2020, ImpediMed announced a contract with AstraZeneca for its SOZO Digital Health Platform to be used in a clinical trial focused on heart failure and chronic kidney disease.
2020-09
PR Newswire
ImpediMed and The US Oncology Network Sign Agreement for Major Roll-Out of SOZOu00ae Technology as Part of Lymphedema Prevention Program
ImpediMed signed a national purchasing agreement with The US Oncology Network in June 2020 for its SOZO Digital Health Platform and Lymphedema Prevention Program, providing access to SOZO for 1,200 physicians.
2020-06
ImpediMed
SOZOu00ae in Physical Therapy Practices Goes Beyond Limitations of BMI to Easily, Effectively Assess Body Composition
An article from January 2019 highlights how ImpediMed's SOZO Digital Health Platform, an FDA-cleared and CE-marked bioimpedance spectroscopy (BIS) device, offers a more effective way to assess body composition in physical therapy by going beyond BMI.
2019-01

Videos

Product demos, reviews, and walkthroughs for SOZO.

View all on YouTube

Frequently Asked Questions

SOZO utilizes bioimpedance spectroscopy (BIS) to non-invasively measure fluid status and tissue composition, providing objective data for clinical decision-making. For lymphedema, it generates an L-Dex score, which can detect subclinical fluid changes before visible swelling occurs. This early detection allows for proactive intervention to potentially prevent progression to chronic lymphedema.
In addition to lymphedema, SOZO can monitor body composition, fluid status in conditions like heart failure, and aid in the assessment of protein-calorie malnutrition. These measurements provide clinicians with a comprehensive snapshot of a patient's physiological status, enabling personalized treatment plans and proactive management across various specialties.
SOZO's BIS technology is highly precise and can detect fluid changes as small as 2.4 tablespoons, offering superior accuracy compared to traditional methods like tape measurement. It provides objective, repeatable data that is validated against gold standard techniques, allowing for earlier and more reliable detection of conditions like lymphedema before physical signs appear.
The L-Dex score is a critical indicator for lymphedema, with a baseline reading taken before cancer treatment serving as a reference. An increase of 6.5 units from the baseline L-Dex score is indicative of early, subclinical lymphedema development, prompting practitioners to implement preventative strategies. This allows for timely intervention, such as garment prescription or exercise, to potentially reverse symptoms or prevent progression to a chronic stage.
SOZO is designed for efficient integration into clinical workflows, with tests taking less than 30 seconds and results immediately available at the point of care or via a cloud-based portal. The platform's data can be automatically integrated with EHR systems for auto-documentation, streamlining access to critical patient trends and analytics for informed clinical decision-making.
Clinical studies, including the PREVENT trial, have demonstrated SOZO's effectiveness in detecting lymphedema early, significantly lowering the progression to chronic lymphedema. Early detection with SOZO and subsequent intervention has shown that a high percentage of patients do not progress to chronic lymphedema. This proactive approach leads to better patient outcomes by enabling timely management and reducing long-term complications.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.